Refractory status epilepticus — benzodiazepine failure protocol, when to use propofol vs midazolam infusion?

1 Answer

**Definition & Management Overview:** Refractory Status Epilepticus (RSE) is defined as seizure activity that continues despite the administration of an initial benzodiazepine and at least one second-line anti-seizure medication (ASM). In the case described, the patient has failed lorazepam and levetiracetam, necessitating immediate escalation to third-line therapy (Stage 4). **Choice of Anesthetic Agent:** Per the Neurocritical Care Society (NCS) and American Epilepsy Society (AES) guidelines, both midazolam and propofol are considered appropriate first-line anesthetic agents for RSE. - **Midazolam:** Benefits include rapid onset and minimal hemodynamic impact compared to other anesthetics. However, it can accumulate in renal failure and has a high rate of tachyphylaxis. - **Propofol:** Offers rapid onset and very rapid offset, facilitating neuro-prognostication. The primary risk is Propofol Infusion Syndrome (PRIS), characterized by metabolic acidosis, rhabdomyolysis, hyperkalemia, and cardiac failure, typically associated with doses >5 mg/kg/hr for >48 hours. **Monitoring & Titration:** The goal of treatment is either seizure cessation or a specific EEG pattern (e.g., burst suppression with 5-20 second intervals). Continuous EEG (cEEG) is mandatory to monitor for non-convulsive status epilepticus (NCSE) after clinical seizures have ceased. **Alternative Agents:** - **Ketamine:** Increasingly used as an early add-on for NMDA receptor antagonism, which may be beneficial as GABA receptors become internalized during prolonged SE. - **Barbiturates (e.g., Pentobarbital):** Reserved for super-refractory SE due to significant risks of hypotension, ileus, and immunosuppression. *This discussion is for educational purposes among medical professionals and does not constitute individual patient advice.*